OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Nephrology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Genetics of diabetes mellitus and diabetes complications	659
COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup	437
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19	410
Kidney involvement in COVID-19 and rationale for extracorporeal therapies	341
Pathophysiology of COVID-19-associated acute kidney injury	269
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality	267
The current and future landscape of dialysis	242
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors	240
Autophagy in kidney homeostasis and disease	235
The immunology of renal cell carcinoma	221
Cellular senescence: the good, the bad and the unknown	209
Mitochondrial quality control in kidney injury and repair	207
Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic	195
WNT–β-catenin signalling — a versatile player in kidney injury and repair	195
Hypertension-induced cognitive impairment: from pathophysiology to public health	183
Plant-based diets to manage the risks and complications of chronic kidney disease	154
Mental health of health-care workers in the COVID-19 era	145
CKD is a key risk factor for COVID-19 mortality	141
Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection	134
Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation	132
Determining the true burden of kidney stone disease	132
Digital pathology and computational image analysis in nephropathology	130
Trajectories of kidney function in diabetes: a clinicopathological update	130
Food as medicine: targeting the uraemic phenotype in chronic kidney disease	127
COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19	120

The effect of HIF on metabolism and immunity	119
Nitric oxide signalling in kidney regulation and cardiometabolic health	106
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease	105
Complexities of the glomerular basement membrane	102
Epidemiology of haemodialysis outcomes	99
Multi-omics integration in the age of million single-cell data	98
COVID-19 vaccination in kidney transplant recipients	98
The fibrogenic niche in kidney fibrosis: components and mechanisms	95
Sustainable Development Goals relevant to kidney health: an update on progress	95
Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative	95
Integrated multi-omics approaches to improve classification of chronic kidney disease	95
Genomic profiling in renal cell carcinoma	94
Impact of the COVID-19 pandemic on clinical research	90
Cisplatin nephrotoxicity: new insights and therapeutic implications	90
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence	89
Organ donation and transplantation: a multi-stakeholder call to action	88
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects	87
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function	86
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup	84
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation	84
COVID-19 vaccines and kidney disease	83
COVID-19: implications for immunosuppression in kidney disease and transplantation	80
The COVID-19 pandemic: consequences for nephrology	77
Minimizing the risk of COVID-19 among patients on dialysis	76
Association of metabolic dysfunction-associated fatty liver disease with kidney disease	73
Conversion of extracellular ATP into adenosine: a master switch in renal health and disease	70
Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury	70
Circular RNAs in kidney disease and cancer	68
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations	68
Kidney and heart failure outcomes associated with SGLT2 inhibitor use	66
Therapeutic advances in COVID-19	65
Immunopathophysiology of trauma-related acute kidney injury	65
Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics	65
Health inequities and the inappropriate use of race in nephrology	65
Trained immunity — basic concepts and contributions to immunopathology	65
Patient-centred approaches for the management of unpleasant symptoms in kidney disease	64
Extracellular vesicles in kidney disease	64
Glomerular hyperfiltration	63
Role of the cGAS–STING pathway in systemic and organ-specific diseases	62
Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus	62
Kidney dendritic cells: fundamental biology and functional roles in health and disease	61
Phenotypic diversity and metabolic specialization of renal endothelial cells	61
The genetics of kidney stone disease and nephrocalcinosis	58
Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury	56
Long COVID and kidney disease	55
Challenges and novel therapies for vascular access in haemodialysis	55
Pathogenesis of autoimmune disease	53
MicroRNAs in kidney injury and disease	53
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease	53
COVID-19 vaccine hesitancy	52

The Mesangial cell — the glomerular stromal cell	51
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease	51
Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease	51
Therapeutic trials in adult FSGS: lessons learned and the road forward	50
The impact of excessive salt intake on human health	50
Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy	49
Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease	47
Key metalloproteinase-mediated pathways in the kidney	46
The gut microbiome and hypertension	46
Vaccination in patients with kidney failure: lessons from COVID-19	45
Membranous nephropathy: new pathogenic mechanisms and their clinical implications	43
Advances in CRISPR therapeutics	43
Modelling kidney disease using ontology: insights from the Kidney Precision Medicine Project	43
Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group	42
Tackling AKI: prevention, timing of dialysis and follow-up	41
Regulated cell death pathways in kidney disease	41
Conceptual advances and evolving terminology in acute kidney disease	40
The therapeutic potential of apelin in kidney disease	40
Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney	40
The evolving story of apolipoprotein L1 nephropathy: the end of the beginning	39
Epidemiology of peritoneal dialysis outcomes	39
Kidney and epigenetic mechanisms of salt-sensitive hypertension	38
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope	37
Complosome — the intracellular complement system	36
Nuclear receptors in podocyte biology and glomerular disease	36
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice	35
Experimental models of acute kidney injury for translational research	34
Advances in fluorescence microscopy techniques to study kidney function	34
Mapping the human kidney using single-cell genomics	34
Unravelling the complex genetics of common kidney diseases: from variants to mechanisms	34
Aquaporin 2 regulation: implications for water balance and polycystic kidney diseases	33
Immunometabolic rewiring of tubular epithelial cells in kidney disease	32
The impact of coronavirus in Brazil: politics and the pandemic	32
Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions	32
Targeting immune cell metabolism in kidney diseases	32
The role of immune cells and mediators in preeclampsia	31
The lymphatics in kidney health and disease	30
Oxalate homeostasis	30
Challenges of access to kidney care for children in low-resource settings	30
Ultrafiltration in critically ill patients treated with kidney replacement therapy	29
SGLT2 inhibitors may offer benefit beyond diabetes	29
The tissue proteome in the multi-omic landscape of kidney disease	28
SARS-CoV-2 in the kidney: bystander or culprit?	28
Nephron overload as a therapeutic target to maximize kidney lifespan	27
The evolving complexity of the collecting duct renin–angiotensin system in hypertension	27
Rare genetic causes of complex kidney and urological diseases	27
The perils of misinformation: when health literacy goes awry	26
Non-invasive molecular imaging of kidney diseases	26
RNA-binding proteins and their role in kidney disease	26
Ethical challenges in nephrology: a call for action	25
Gasdermins and pyroptosis in the kidney	25
Progress in xenotransplantation: overcoming immune barriers	24
The nephropathy of sickle cell trait and sickle cell disease	24
Unconventional T cells and kidney disease	24
The roles of tertiary lymphoid structures in chronic diseases	24
Activation and regulation of alloreactive T cell immunity in solid organ transplantation	23
Wearable artificial kidney: problems, progress and prospects	22
Artificial intelligence-enabled decision support in nephrology	22
Cardiac metabolic remodelling in chronic kidney disease	22
Long COVID: long-term health outcomes and implications for policy and research	21
Biomimetic models of the glomerulus	21
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury	20
Youth-onset type 2 diabetes mellitus: an urgent challenge	20
Nutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases	20
Stony the road we trod: towards racial justice in kidney care	20
The role of lysosomes in metabolic and autoimmune diseases	20